These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 29906252)

  • 21. WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies.
    Oji Y; Inoue M; Takeda Y; Hosen N; Shintani Y; Kawakami M; Harada T; Murakami Y; Iwai M; Fukuda M; Nishida S; Nakata J; Nakae Y; Takashima S; Shirakata T; Nakajima H; Hasegawa K; Kida H; Kijima T; Morimoto S; Fujiki F; Tsuboi A; Morii E; Morita S; Sakamoto J; Kumanogoh A; Oka Y; Okumura M; Sugiyama H
    Int J Cancer; 2018 Jun; 142(11):2375-2382. PubMed ID: 29322496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity in advanced cancer patients with thymic malignancies enrolled in early clinical drug development programs (Phase I trials) at Gustave Roussy.
    Kossai M; Duchemann B; Boutros C; Caramella C; Hollebecque A; Angevin E; Gazzah A; Bahleda R; Ileana E; Massard C; Vielh P; Soria JC; Besse B
    Lung Cancer; 2015 Sep; 89(3):306-10. PubMed ID: 26160757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anlotinib in patients with relapsed or refractory thymic epithelial tumors: a study of 50 cases.
    Wang CL; Zhao YZ; Zhang Q; Zeng WQ; Jia TY; Zhu L; Fang WT; Fu XL
    Anticancer Drugs; 2023 Aug; 34(7):852-856. PubMed ID: 36729892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.
    Frumovitz M; Westin SN; Salvo G; Zarifa A; Xu M; Yap TA; Rodon AJ; Karp DD; Abonofal A; Jazaeri AA; Naing A
    Gynecol Oncol; 2020 Sep; 158(3):570-575. PubMed ID: 32534809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.
    Sato J; Satouchi M; Itoh S; Okuma Y; Niho S; Mizugaki H; Murakami H; Fujisaka Y; Kozuki T; Nakamura K; Nagasaka Y; Kawasaki M; Yamada T; Machida R; Kuchiba A; Ohe Y; Yamamoto N
    Lancet Oncol; 2020 Jun; 21(6):843-850. PubMed ID: 32502444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.
    Zucali PA; De Pas T; Palmieri G; Favaretto A; Chella A; Tiseo M; Caruso M; Simonelli M; Perrino M; De Vincenzo F; Toffalorio F; Damiano V; Pasello G; Garbella E; Ali M; Conforti F; Ottaviano M; Cioffi A; De Placido S; Giordano L; Bertossi M; Destro A; Di Tommaso L; Santoro A
    J Clin Oncol; 2018 Feb; 36(4):342-349. PubMed ID: 29240542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
    N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
    J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study.
    Katsuya Y; Horinouchi H; Seto T; Umemura S; Hosomi Y; Satouchi M; Nishio M; Kozuki T; Hida T; Sukigara T; Nakamura K; Kuchiba A; Ohe Y
    Eur J Cancer; 2019 May; 113():78-86. PubMed ID: 30991261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
    Giaccone G; Rajan A; Berman A; Kelly RJ; Szabo E; Lopez-Chavez A; Trepel J; Lee MJ; Cao L; Espinoza-Delgado I; Spittler J; Loehrer PJ
    J Clin Oncol; 2011 May; 29(15):2052-9. PubMed ID: 21502553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).
    Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C
    Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
    Zhu AX; Finn RS; Edeline J; Cattan S; Ogasawara S; Palmer D; Verslype C; Zagonel V; Fartoux L; Vogel A; Sarker D; Verset G; Chan SL; Knox J; Daniele B; Webber AL; Ebbinghaus SW; Ma J; Siegel AB; Cheng AL; Kudo M;
    Lancet Oncol; 2018 Jul; 19(7):940-952. PubMed ID: 29875066
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Response to Pembrolizumab in a Patient with Relapsing Thymoma.
    Zander T; Aebi S; Rast AC; Zander A; Winterhalder R; Brand C; Diebold J; Gautschi O
    J Thorac Oncol; 2016 Dec; 11(12):e147-e149. PubMed ID: 27498287
    [No Abstract]   [Full Text] [Related]  

  • 35. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study.
    Balar AV; Castellano D; O'Donnell PH; Grivas P; Vuky J; Powles T; Plimack ER; Hahn NM; de Wit R; Pang L; Savage MJ; Perini RF; Keefe SM; Bajorin D; Bellmunt J
    Lancet Oncol; 2017 Nov; 18(11):1483-1492. PubMed ID: 28967485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma.
    Doi T; Piha-Paul SA; Jalal SI; Saraf S; Lunceford J; Koshiji M; Bennouna J
    J Clin Oncol; 2018 Jan; 36(1):61-67. PubMed ID: 29116900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.
    Girard N; Ponce Aix S; Cedres S; Berghmans T; Burgers S; Toffart AC; Popat S; Janssens A; Gervais R; Hochstenbag M; Silva M; Burger IA; Prosch H; Stahel R; Xenophontos E; Pretzenbaher Y; Neven A; Peters S
    ESMO Open; 2023 Jun; 8(3):101576. PubMed ID: 37285717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma.
    Gbolahan OB; Porter RF; Salter JT; Yiannoutsos C; Burns M; Chiorean EG; Loehrer PJ
    J Thorac Oncol; 2018 Dec; 13(12):1940-1948. PubMed ID: 30121390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study.
    Emens LA; Cruz C; Eder JP; Braiteh F; Chung C; Tolaney SM; Kuter I; Nanda R; Cassier PA; Delord JP; Gordon MS; ElGabry E; Chang CW; Sarkar I; Grossman W; O'Hear C; Fassò M; Molinero L; Schmid P
    JAMA Oncol; 2019 Jan; 5(1):74-82. PubMed ID: 30242306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
    Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
    Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.